Skip to content

Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds

Efficacy of SynEx™ Wound Rinse in Civilian Surrogates of Combat Injury Wounds

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05743283
Enrollment
100
Registered
2023-02-24
Start date
2023-04-12
Completion date
2025-09-30
Last updated
2024-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Heal

Brief summary

The purpose of this interventional study is to compare SynEx Wound Cleanser with the current routine care (Saline) in traumatic wounds. Participants with gunshot, penetrating or burn wounds who participate will be asked to attend up to four study visits, use the assigned wound cleanser and complete brief surveys about their healing and well-being related to the wound healing.

Interventions

DEVICESynEx Wound Cleanser

SynEx is a concentrated form of SynePure®, an FDA 510(k) cleared aqueous, osmotically balanced wound cleanser containing patented chitosan derivatives. The ingredients are USP purified water, chitosan arginine (a patented chitosan derivative), sorbitol powder, and betaine. SynEx cleanser is packaged in a collapsible plastic pouch for reconstitution in water before debriding and cleansing a wound.

OTHERSaline

The saline solution is composed of water and salt. It is packaged in a collapsible plastic pouch.

Sponsors

United States Department of Defense
CollaboratorFED
Medical Technology Enterprise Consortium
CollaboratorUNKNOWN
Synedgen, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Parallel-group, comparator-controlled interventional study to assess clinical efficacy of SynEx Wound Cleanser.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Acute penetrating, puncture and burn wounds of the upper or lower extremity that meet the inclusion and

Exclusion criteria

for the wound type: 1. Penetrating, puncture or laceration wounds: stage II-III (partial to full thickness loss of dermis) excluding diabetic or venous wounds, and pressure ulcers and perforated wounds (except gunshot wounds) and wounds with exposed bones, facia or muscle. 2. Gunshot wounds (GSW): Grade I - II on the Red Cross Classification of War Wounds6 (diameter of entry + exit wounds \< 10 cm, wound cavity or not, no fracture or fraction without clinically significant comminution). Non-penetrating, penetrating, or perforated GSW are included. GSW with suspected vascular injuries or nerve damage are excluded. 3. Burns: partial thickness injury ≤ 9% TBSA. Thermal burn from flame or scald, chemical burns, and electrical burn are included. Radiation and frostbite burns are excluded. 2. Males and females ≥18 years old. 3. Has access to a computer or mobile device for telepresence visits. 4. Able to give informed consent and willing to comply with all required study procedures.

Design outcomes

Primary

MeasureTime frameDescription
Wound healing environment composite score14 daysThe composite score is a summation of wound characteristics such size, depth, edges and undermining. Scores range from range of 13 to 60, representing wound regeneration to degeneration respectively).

Countries

United States

Contacts

Primary ContactShenda Baker, PhD
sb@synedgen.com(909) 447-6858
Backup ContactKaveri Parker, PhD
kp@synedgen.com(909) 447-6858

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026